Ftse Mib
36.191,17
-0,03%
DAX
21.282,18
-0,48%
S&P 500
6.012,28
-1,46%
NASDAQ
19.341,83
-3,07%
Bitcoin
103.064,03
0,98%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Olema Pharmaceuticals Inc (OLMA) Olema Pharmaceuticals Inc (OLMA) Notizie

OLMA

Olema Pharmaceuticals (OLMA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OLMA
DataOraFonteTitoloSimboloCompagnia
16/01/202506:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
15/01/202522:46Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OLMAOlema Pharmaceuticals Inc
15/01/202522:44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
13/01/202522:24Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
13/01/202513:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
06/01/202522:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
03/01/202522:30GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
02/01/202513:00GlobeNewswire Inc.Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
19/12/202400:52Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
18/12/202401:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
13/12/202422:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
11/12/202422:30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:OLMAOlema Pharmaceuticals Inc
10/12/202413:00GlobeNewswire Inc.Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer SymposiumNASDAQ:OLMAOlema Pharmaceuticals Inc
09/12/202413:00GlobeNewswire Inc.Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 InhibitorNASDAQ:OLMAOlema Pharmaceuticals Inc
02/12/202413:00GlobeNewswire Inc.Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private PlacementNASDAQ:OLMAOlema Pharmaceuticals Inc
25/11/202423:30GlobeNewswire Inc.Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer SymposiumNASDAQ:OLMAOlema Pharmaceuticals Inc
25/11/202401:27PR Newswire (US)Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsNASDAQ:OLMAOlema Pharmaceuticals Inc
14/11/202422:34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/11/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/11/202422:01GlobeNewswire Inc.Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
06/11/202413:01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
23/10/202413:00GlobeNewswire Inc.Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024NASDAQ:OLMAOlema Pharmaceuticals Inc
09/10/202413:00GlobeNewswire Inc.Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:OLMAOlema Pharmaceuticals Inc
21/08/202413:00GlobeNewswire Inc.Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
06/08/202422:02GlobeNewswire Inc.Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
07/06/202400:49Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
28/05/202413:03GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in JuneNASDAQ:OLMAOlema Pharmaceuticals Inc
15/05/202413:01GlobeNewswire Inc.Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422:02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202413:02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OLMA

La tua Cronologia

BIT
UC6124
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network